Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

被引：0

作者：

Jiang, Brian Gabriel ^{[1
]}

Kim, Dong-Wook ^{[2
]}

Shih, Lee-Yung ^{[3
]}

Chuah, Charles ^{[4
,5
]}

Than, Hein ^{[4
]}

Kuo, Ming-Chung ^{[6
,7
]}

Li, HuiHua ^{[8
]}

Allen, John Carson, Jr. ^{[9
]}

See, Lionel K. Y. ^{[10
]}

Yap, Bernard K. C. ^{[10
]}

Goh, Yeow-Tee ^{[4
,10
]}

机构：

[1] Duke Univ, Sch Med, Durham, NC USA

[2] St Marys Hosp, Dept Haematol, Seoul, South Korea

[3] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Dept Hematol Oncol, Taipei, Taiwan

[4] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[5] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Signature Res Program, Singapore, Singapore

[6] Chang Gung Mem Hosp Linkou, Taoyuan, Taiwan

[7] Chang Gung Univ, Taoyuan, Taiwan

[8] Hlth Serv Res, Singapore, Singapore

[9] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore

[10] Duke NUS Grad Med Sch, Singapore, Singapore

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
Markus Pfirrmann
Richard E. Clark
Witold Prejzner
Michael Lauseker
Michele Baccarani
Susanne Saussele
François Guilhot
Sonja Heibl
Rüdiger Hehlmann
Edgar Faber
Anna Turkina
Gert Ossenkoppele
Martin Höglund
Andrey Zaritskey
Laimonas Griskevicius
Ulla Olsson-Strömberg
Hele Everaus
Perttu Koskenvesa
Boris Labar
Tomasz Sacha
Daniela Zackova
Francisco Cervantes
Adriana Colita
Irena Zupan
Andrija Bogdanovic
Fausto Castagnetti
Joëlle Guilhot
Joerg Hasford
Andreas Hochhaus
Verena S. Hoffmann
[J]. Leukemia, 2020, 34 : 2138 - 2149
[2] The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
Pfirrmann, Markus
Clark, Richard E.
Prejzner, Witold
Lauseker, Michael
Baccarani, Michele
Saussele, Susanne
Guilhot, Francois
Heibl, Sonja
Hehlmann, Rudiger
Faber, Edgar
Turkina, Anna
Ossenkoppele, Gert
Hoglund, Martin
Zaritskey, Andrey
Griskevicius, Laimonas
Olsson-Stromberg, Ulla
Everaus, Hele
Koskenvesa, Perttu
Labar, Boris
Sacha, Tomasz
Zackova, Daniela
Cervantes, Francisco
Colita, Adriana
Zupan, Irena
Bogdanovic, Andrija
Castagnetti, Fausto
Guilhot, Joelle
Hasford, Joerg
Hochhaus, Andreas
Hoffmann, Verena S.
[J]. LEUKEMIA, 2020, 34 (08) : 2138 - 2149
[3] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
Ganguly, Sandip
Lakshmaiah, K. C.
Jacob, Linu Abraham
Babu, Suresh
Dasappa, Lokanatha
Babu, K. S. Govind
[J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 82 - 86
[4] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
Sandip Ganguly
K. C. Lakshmaiah
Linu Abraham Jacob
Suresh Babu
Lokanatha Dasappa
K. S. Govind Babu
[J]. Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 82 - 86
[5] The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia
Pfirrmann, Markus
Hasford, Joerg
Saussele, Susanne
Turkina, Anna
Prejzner, Witold
Luis Steegmann, Juan
Simonsson, Bengt
Zaritskey, Andrey
Colita, Adriana
Zackova, Daniela
Janssen, Jeroen
Cervantes, Francisco
Indrak, Karel
Guilhot, Joelle
Hehlmann, Ruediger
Baccarani, Michele
[J]. BLOOD, 2015, 126 (23)
[6] Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
Xia, Leiming
Qian, Wei
Yang, Mingzhen
Li, Qingsheng
Liu, Fei
Xie, Yanyan
[J]. ONCOTARGETS AND THERAPY, 2015, 8 : 2485 - 2492
[7] Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib
Ko, Po-Shen
Yu, Yuan-Bin
Liu, Yao-Chung
Wu, Yi-Tsui
Hung, Man-Hsin
Gau, Jyh-Pyng
Liu, Chia-Jen
Hsiao, Liang-Tsai
Chena, Po-Min
Chiou, Tzeon-Jye
Liu, Chun-Yu
Liu, Jin-Hwang
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1737 - 1744
[8] The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients
Castagnetti, Fausto
Gugliotta, Gabriele
Breccia, Massimo
Stagno, Fabio
Specchia, Giorgina
Levato, Luciano
Martino, Bruno
D'Adda, Mariella
Abruzzese, Elisabetta
Pregno, Patrizia
Tiribelli, Mario
Iurlo, Alessandra
Intermesoli, Tamara
Scortechini, Anna Rita
Cavazzini, Francesco
Fava, Carmen
Bonifacio, Massimiliano
Salvucci, Marzia
Bocchia, Monica
Caocci, Giovanni
Gozzini, Antonella
Bergamaschi, Micaela
Soverini, Simona
Foa, Robin
Martinelli, Giovanni
Cavo, Michele
Saglio, Giuseppe
Pane, Fabrizio
Baccarani, Michele
Rosti, Gianantonio
[J]. BLOOD, 2018, 132
[9] The EUTOS long-term survival (ELTS) score is superior to the Sokal score for prognosis of probabilities of dying of chronicphase chronic myeloid leukaemia
Pfirrmann, M.
Baccarani, M.
Saussele, S.
Faber, E.
Bogdanovic, A.
Clark, R.
Hehlmann, R.
Hoffmann, V. S.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 140 - 141
[10] Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib
Jose Francis
Biswajit Dubashi
Rajan Sundaram
Suresh Chandra Pradhan
Adithan Chandrasekaran
[J]. Medical Oncology, 2015, 32

← 1 2 3 4 5 →